“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.
Stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT) has lower rates of incontinence and sexual dysfunction, with a small trade-off in bowel bother, compared…
Stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT) has lower rates of incontinence and sexual dysfunction, with a small trade-off in bowel bother, compared…
Purpose:Several factors influence recurrence after urethral stricture repair. The impact of socioeconomic factors on stricture recurrence after urethroplasty is poorly understood. This study aims to…
“These types of technologies can really make office urology much more efficient, which I think is very, very promising and one of the most promising…
European Urology Today (EUT) is the official newsletter of the EAU. It is produced five times a year, informing members on announcements, news about the…
Our final episode of the year! And we end with a very seasonal celebration of single-port surgery and the Boxing Day Test with Australia playing…
“As a result of the changes and the programmed phase-in of the changes, the cystoscopy code total RVU for the office setting will be 8%…
Registration for the 2025 AUA Innovation Nexus Conference is now open! As you plan to attend this groundbreaking event, please review these key details. For…
The approval is supported by data from the phase 3 CheckMate-67T trial.
As the year comes to a close, we revisit some of this year’s top content on kidney stone management.
